215 related articles for article (PubMed ID: 25398452)
1. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy.
Apellániz-Ruiz M; Lee MY; Sánchez-Barroso L; Gutiérrez-Gutiérrez G; Calvo I; García-Estévez L; Sereno M; García-Donás J; Castelo B; Guerra E; Leandro-García LJ; Cascón A; Johansson I; Robledo M; Ingelman-Sundberg M; Rodríguez-Antona C
Clin Cancer Res; 2015 Jan; 21(2):322-8. PubMed ID: 25398452
[TBL] [Abstract][Full Text] [Related]
2. Targeted Sequencing Reveals Low-Frequency Variants in
Apellániz-Ruiz M; Tejero H; Inglada-Pérez L; Sánchez-Barroso L; Gutiérrez-Gutiérrez G; Calvo I; Castelo B; Redondo A; García-Donás J; Romero-Laorden N; Sereno M; Merino M; Currás-Freixes M; Montero-Conde C; Mancikova V; Åvall-Lundqvist E; Green H; Al-Shahrour F; Cascón A; Robledo M; Rodríguez-Antona C
Clin Cancer Res; 2017 Mar; 23(5):1227-1235. PubMed ID: 27582484
[No Abstract] [Full Text] [Related]
3. Relevance of the CYP3A4*20 variant as a predictor of paclitaxel-induced neuropathy in the Spanish population.
Riera P; Apellániz MV; Salazar J
Med Clin (Barc); 2018 Feb; 150(4):163-164. PubMed ID: 29054579
[No Abstract] [Full Text] [Related]
4. Cytochrome P450 Oxidoreductase (POR) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103.
Shen F; Jiang G; Philips S; Gardner L; Xue G; Cantor E; Ly RC; Osei W; Wu X; Dang C; Northfelt D; Skaar T; Miller KD; Sledge GW; Schneider BP
Clin Cancer Res; 2023 Jul; 29(13):2494-2500. PubMed ID: 37126018
[TBL] [Abstract][Full Text] [Related]
5. Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
Sánchez-Barroso L; Apellaniz-Ruiz M; Gutiérrez-Gutiérrez G; Santos M; Roldán-Romero JM; Curras M; Remacha L; Calsina B; Calvo I; Sereno M; Merino M; García-Donas J; Castelo B; Guerra E; Letón R; Montero-Conde C; Cascón A; Inglada-Pérez L; Robledo M; Rodríguez-Antona C
Oncologist; 2019 Aug; 24(8):e784-e792. PubMed ID: 30470691
[TBL] [Abstract][Full Text] [Related]
6. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
Lam SW; Frederiks CN; van der Straaten T; Honkoop AH; Guchelaar HJ; Boven E
Br J Cancer; 2016 Nov; 115(11):1335-1342. PubMed ID: 27736846
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients.
Robertson J; Raizer J; Hodges JS; Gradishar W; Allen JA
J Peripher Nerv Syst; 2018 Jun; 23(2):129-133. PubMed ID: 29696771
[TBL] [Abstract][Full Text] [Related]
8. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.
Schneider BP; Lai D; Shen F; Jiang G; Radovich M; Li L; Gardner L; Miller KD; O'Neill A; Sparano JA; Xue G; Foroud T; Sledge GW
Oncotarget; 2016 Dec; 7(50):82244-82253. PubMed ID: 27732968
[TBL] [Abstract][Full Text] [Related]
9. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
Baldwin RM; Owzar K; Zembutsu H; Chhibber A; Kubo M; Jiang C; Watson D; Eclov RJ; Mefford J; McLeod HL; Friedman PN; Hudis CA; Winer EP; Jorgenson EM; Witte JS; Shulman LN; Nakamura Y; Ratain MJ; Kroetz DL
Clin Cancer Res; 2012 Sep; 18(18):5099-109. PubMed ID: 22843789
[TBL] [Abstract][Full Text] [Related]
10. Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.
Leandro-García LJ; Leskelä S; Jara C; Gréen H; Avall-Lundqvist E; Wheeler HE; Dolan ME; Inglada-Perez L; Maliszewska A; de Cubas AA; Comino-Méndez I; Mancikova V; Cascón A; Robledo M; Rodríguez-Antona C
Clin Cancer Res; 2012 Aug; 18(16):4441-8. PubMed ID: 22718863
[TBL] [Abstract][Full Text] [Related]
11. Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.
Sundar R; Jeyasekharan AD; Pang B; Soong RC; Kumarakulasinghe NB; Ow SG; Ho J; Lim JS; Tan DS; Wilder-Smith EP; Bandla A; Tan SS; Asuncion BR; Fazreen Z; Hoppe MM; Putti TC; Poh LM; Goh BC; Lee SC
PLoS One; 2016; 11(10):e0164319. PubMed ID: 27716814
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.
Leandro-García LJ; Inglada-Pérez L; Pita G; Hjerpe E; Leskelä S; Jara C; Mielgo X; González-Neira A; Robledo M; Avall-Lundqvist E; Gréen H; Rodríguez-Antona C
J Med Genet; 2013 Sep; 50(9):599-605. PubMed ID: 23776197
[TBL] [Abstract][Full Text] [Related]
13. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
Sissung TM; Mross K; Steinberg SM; Behringer D; Figg WD; Sparreboom A; Mielke S
Eur J Cancer; 2006 Nov; 42(17):2893-6. PubMed ID: 16950614
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
Leskelä S; Jara C; Leandro-García LJ; Martínez A; García-Donas J; Hernando S; Hurtado A; Vicario JC; Montero-Conde C; Landa I; López-Jiménez E; Cascón A; Milne RL; Robledo M; Rodríguez-Antona C
Pharmacogenomics J; 2011 Apr; 11(2):121-9. PubMed ID: 20212519
[TBL] [Abstract][Full Text] [Related]
15. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
Wheeler HE; Gamazon ER; Wing C; Njiaju UO; Njoku C; Baldwin RM; Owzar K; Jiang C; Watson D; Shterev I; Kubo M; Zembutsu H; Winer EP; Hudis CA; Shulman LN; Nakamura Y; Ratain MJ; Kroetz DL; ; Cox NJ; Dolan ME
Clin Cancer Res; 2013 Jan; 19(2):491-9. PubMed ID: 23204130
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Ghoreishi Z; Keshavarz S; Asghari Jafarabadi M; Fathifar Z; Goodman KA; Esfahani A
BMC Cancer; 2018 Oct; 18(1):958. PubMed ID: 30290775
[TBL] [Abstract][Full Text] [Related]
17. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
Chhibber A; Mefford J; Stahl EA; Pendergrass SA; Baldwin RM; Owzar K; Li M; Winer EP; Hudis CA; Zembutsu H; Kubo M; Nakamura Y; McLeod HL; Ratain MJ; Shulman LN; Ritchie MD; Plenge RM; Witte JS; Kroetz DL
Pharmacogenomics J; 2014 Aug; 14(4):336-42. PubMed ID: 24513692
[TBL] [Abstract][Full Text] [Related]
18. Association between Met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathy.
Azoulay D; Leibovici A; Sharoni R; Shaoul E; Gross B; Braester A; Goldberg H
Breast Cancer Res Treat; 2015 Oct; 153(3):703-4. PubMed ID: 26272744
[No Abstract] [Full Text] [Related]
19. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
Hertz DL; Motsinger-Reif AA; Drobish A; Winham SJ; McLeod HL; Carey LA; Dees EC
Breast Cancer Res Treat; 2012 Jul; 134(1):401-10. PubMed ID: 22527101
[TBL] [Abstract][Full Text] [Related]
20. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.
de Graan AJ; Elens L; Sprowl JA; Sparreboom A; Friberg LE; van der Holt B; de Raaf PJ; de Bruijn P; Engels FK; Eskens FA; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
Clin Cancer Res; 2013 Jun; 19(12):3316-24. PubMed ID: 23640974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
